In the brain, compelling evidence demonstrated that the inhibition of plasma kallikrein reduced matrix metalloproteinase-9 activity [82] following stroke and tissue plasminogen activator (tPA) therapy. The gene discussed is MMP9; the disease is stroke disorder.